These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 31805528)

  • 1. Are Surrogate Endpoints Unbiased Metrics in Clinical Benefit Scores of the ASCO Value Framework?
    Cheng S; Cheung MC; Jiang DM; McDonald E; Arciero VS; Ezeife DA; Rahmadian A; Chambers A; Sabarre KA; Parmar A; Chan KKW
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1489-1496. PubMed ID: 31805528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exploration of modified progression-free survival as a novel surrogate endpoint for overall survival in immuno-oncology trials.
    Wang ZX; Wu HX; Xie L; Lin WH; Liang F; Li J; Yang ZM; Xu RH
    J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33795385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Do Surrogate Endpoints Better Correlate with Overall Survival in Studies That Did Not Allow for Crossover or Reported Balanced Postprogression Treatments? An Application in Advanced Non-Small Cell Lung Cancer.
    Hashim M; Pfeiffer BM; Bartsch R; Postma M; Heeg B
    Value Health; 2018 Jan; 21(1):9-17. PubMed ID: 29304946
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis.
    Kaufman HL; Schwartz LH; William WN; Sznol M; Fahrbach K; Xu Y; Masson E; Vergara-Silva A
    J Cancer Res Clin Oncol; 2018 Nov; 144(11):2245-2261. PubMed ID: 30132118
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Progression-free survival is simply a measure of a drug's effect while administered and is not a surrogate for overall survival.
    Wilkerson J; Fojo T
    Cancer J; 2009; 15(5):379-85. PubMed ID: 19826357
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials.
    Mushti SL; Mulkey F; Sridhara R
    Clin Cancer Res; 2018 May; 24(10):2268-2275. PubMed ID: 29326281
    [No Abstract]   [Full Text] [Related]  

  • 7. Assessment of Whether the American Society of Clinical Oncology's Value Framework and the European Society for Medical Oncology's Magnitude of Clinical Benefit Scale Measure Absolute or Relative Clinical Survival Benefit: An Analysis of Randomized Clinical Trials.
    Saluja R; Everest L; Cheng S; Cheung M; Chan KKW
    JAMA Oncol; 2019 Aug; 5(8):1188-1194. PubMed ID: 31095255
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship between progression-free survival and overall survival in patients with advanced non-small cell lung cancer treated with anticancer agents after first-line treatment failure.
    Suzuki H; Hirashima T; Okamoto N; Yamadori T; Tamiya M; Morishita N; Shiroyama T; Takeoka S; Osa A; Azuma Y; Kawase I
    Asia Pac J Clin Oncol; 2015 Jun; 11(2):121-8. PubMed ID: 24811212
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Estimation of Study Time Reduction Using Surrogate End Points Rather Than Overall Survival in Oncology Clinical Trials.
    Chen EY; Joshi SK; Tran A; Prasad V
    JAMA Intern Med; 2019 May; 179(5):642-647. PubMed ID: 30933235
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation.
    Tanaka K; Kawano M; Iwasaki T; Itonaga I; Tsumura H
    BMC Cancer; 2019 Jan; 19(1):56. PubMed ID: 30634944
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings.
    Hua T; Gao Y; Zhang R; Wei Y; Chen F
    BMC Cancer; 2022 Sep; 22(1):1022. PubMed ID: 36171546
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer.
    Ito K; Miura S; Sakaguchi T; Murotani K; Horita N; Akamatsu H; Uemura K; Morita S; Yamamoto N
    Lung Cancer; 2019 Feb; 128():113-119. PubMed ID: 30642442
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting Real-World Effectiveness of Cancer Therapies Using Overall Survival and Progression-Free Survival from Clinical Trials: Empirical Evidence for the ASCO Value Framework.
    Lakdawalla DN; Shafrin J; Hou N; Peneva D; Vine S; Park J; Zhang J; Brookmeyer R; Figlin RA
    Value Health; 2017; 20(7):866-875. PubMed ID: 28712615
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials.
    Foster NR; Qi Y; Shi Q; Krook JE; Kugler JW; Jett JR; Molina JR; Schild SE; Adjei AA; Mandrekar SJ
    Cancer; 2011 Mar; 117(6):1262-71. PubMed ID: 20960500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies.
    Roviello G; Andre F; Venturini S; Pistilli B; Curigliano G; Cristofanilli M; Rosellini P; Generali D
    Eur J Cancer; 2017 Nov; 86():257-265. PubMed ID: 29055841
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-Value Cancer Care and the Problem With Surrogate Endpoints in the Quality/Cost Equation.
    Chino F
    J Natl Compr Canc Netw; 2019 Dec; 17(12):1569-1570. PubMed ID: 31805532
    [No Abstract]   [Full Text] [Related]  

  • 17. The value of surrogate endpoints for predicting real-world survival across five cancer types.
    Shafrin J; Brookmeyer R; Peneva D; Park J; Zhang J; Figlin RA; Lakdawalla DN
    Curr Med Res Opin; 2016; 32(4):731-9. PubMed ID: 26743800
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Meaningful endpoints for therapies approved for hematologic malignancies.
    Smith BD; DeZern AE; Bastian AW; Durie BGM
    Cancer; 2017 May; 123(10):1689-1694. PubMed ID: 28222220
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized trials and endpoints in advanced HCC: Role of PFS as a surrogate of survival.
    Llovet JM; Montal R; Villanueva A
    J Hepatol; 2019 Jun; 70(6):1262-1277. PubMed ID: 30943423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: A critical review.
    Savina M; Gourgou S; Italiano A; Dinart D; Rondeau V; Penel N; Mathoulin-Pelissier S; Bellera C
    Crit Rev Oncol Hematol; 2018 Mar; 123():21-41. PubMed ID: 29482777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.